-
New advances in monoclonal antibody therapy for a variety of diseases!
Time of Update: 2020-11-10
In this article, we compiled several important research results to jointly interpret the new advances made by scientists in the field of monoclonal antibody therapy and share them with you! Picture:
-
Wuhan large-scale new crown antibody test data published in JAMA sub-journal
Time of Update: 2020-11-10
recently, JAMA Network Open, a sub-issue of the Journal of the American Medical Association, published the results of a survey on the sero-positive rate of new coronary antibodies in people in Wuhan.
-
Interpretation of important research results published by Chinese scientists on CNS! (August-October 2020)
Time of Update: 2020-11-09
image Source: Nature: Chinese scientists discover new coronavirus S-RBD vaccine can induce protective immune response doi:10.1038/s41586-020-25 Now, scientists have confirmed that THES-CoV and MERS-CoV's RBD contains major structurally dependent neutrality and cousins, and is able to produce powerful neutral antibodies in immune animals, thus promising vaccine development targets.
-
Scientists have a deep understanding of the molecular mechanisms by which cancer cells are resistant to therapy or are expected to help develop new individualized anti-cancer therapies!
Time of Update: 2020-11-09
October 29, 2020 // -- An An Integrative Gene Gene Gene and Mathematical Flux Balance Analysis Designs Targeted Red, published in the international magazine Cansr Research In a study by Ox Possibilities in Melanoma Cells, scientists from Vanderburg University and others identified a specific enzyme that may still keep tumor cells growing while cancer drugs are being treated, and the findings may provide scientists with new ideas and hope for developing new ways to block cancer cell growth.
-
Regenerative meta-new crown and antibody combination therapy reached the clinical end of phase 2/3
Time of Update: 2020-11-09
preliminary clinical trial results previously published by Regenerative Meta have shown that REGN-COV2 can reduce viral load and reduce the time required for symptom relief in patients treating non-hospitalized COVID-19 patients .
-
Heavyweight article focuses on new advances in body inflammation research!
Time of Update: 2020-11-09
but in a new study recently published in the journal Frontiers in Immunology, scientists found that a specific type of molecule may stimulate stem cell regeneration, reversing inflammation caused by periodontage disease.
-
Scientists have developed a variety of new technologies that can quickly detect COVID-19!
Time of Update: 2020-11-09
: Nat Biotechnol: Developing a new technology for highly sensitive detection of COVID-19 doi:10.1038/s41587-020-0631-z In a recent study published in the journal Nature Biotechnology, scientists from Duke National School of Medicine worked closely with the National Center for Infectious Diseases (NCID, Singapore Institute of Molecular and Cell Biology (IMCB) to develop a new test kit called sVNT.
-
Nature: Glutamine prevents muscle injury and aging
Time of Update: 2020-11-08
researchers have shown that strengthening this metabolic crosstalk with GLUD1 inhibitors promotes the release of glutamine and improves muscle regeneration and body function in experimental models of muscle degeneration such as trauma, local isoemia and aging.
-
New drug for pediatric psoriasis! Novarca Cosentyx first-line treatment: quick and powerful removal of skin damage, improve the quality of life!
Time of Update: 2020-11-08
October 31, 2020 // -- Novartis recently released data from two key international Phase 3 studies that show moderate to severe spots between the ages of 6 and 18 In children and adolescents with psoriasis, Cosentyx (Chinese product name: good, generic name: secukinumab, Skuchiyu monoanti, commonly known as "Sukin monoanti" ) provides fast, powerful skin patch removal and significantly improves quality of life.
-
Targeted therapy for eosinophil disease! GlaxoSmithKline's Nucala enters EU review: Treating 3 new allergies!
Time of Update: 2020-11-08
October 30, 2020 // --- GlaxoSmithKline (GSK) recently announced that the European Medicines Agency (EMA) has accepted marketing of the anti-inflammatory drug Nucala (mepolizumab, Mepolizumab) Authorization Application (MAA) for the treatment of 3 new adaptations: high eosinophil syndrome (HES), chronic nasal-sinusitis with nasal polyps (CRSwNP), and acidoblastoid granulocytic multivascularitis (EGPA).
-
Science: Most people produce a strong antibody response to SARS-CoV-2, and the antibody response remains relatively stable for at least five months
Time of Update: 2020-11-08
October 31, 2020 /--- In a new study, researchers from the Icahn School of Medicine at Mount Sinai found that the vast majority of people infected with mild to moderate COVID-19 develop a strong anti
-
New drugs for special dermatitis! Pfizer's next-generation oral JAK1 inhibitor abrocitinib enters the review in the US and Europe!
Time of Update: 2020-11-08
Oct 30, 2020 // -- Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has accepted abrocitinib (100 mg, 200 mg) of new drugs Application (NDA) and granted priority review of the drug, a once-a-day oral JAK1 inhibitor used to treat patients aged ≥12 with moderate to severe endexual dermatitis (AD).
-
Plos Neg Trop Dis: The COVID19 outbreak affects the spread of dengue virus
Time of Update: 2020-11-08
now, researchers reporting in the journal PLOS Neglected Tropical Diseases have found that social distance has led to a significant increase in dengue infections in Thailand, while dengue fever in Singapore or Malaysia has not changed.
-
New asthma drug! AstraZenega Fasenra Phase 3 Clinical: Eliminate oral corticosteroid (OCS) needs in most patients!
Time of Update: 2020-11-08
PONENTE is a multi-center, open-label, single-arm, IIIb phase trial conducted to assess the effectiveness and safety of daily OCS use after receiving high-dose inhaled corticosteroids (ICS), long-acting beta-2 astrations (LABA), long-term use of OCS therapy, co-use or non-addition of additional asthma control drugs.
-
iScience Anatomy! How do shortened immune system subjects help regulate cell activity?
Time of Update: 2020-11-08
October 31, 2020 // -- A recent publication in the international journal iScience entitled "Non-full-length Water-Soluble CXCR4QTY and CCR5QTY Chemokine Receptors: Factor for Connected Truncate" But Functional Membrane Receptors" study, by scientists from institutions such as the Massachusetts Institute of Technology, found that shortened versions of immuno-related protein receptors that have long been considered incomplete and inseroid, or can be combined with natural counterparts on cell membranes, may indicate new drugs, therapies, and bionic body parts.
-
Several studies have revealed the effects of cholesterol on human health
Time of Update: 2020-11-08
In a new study, researchers at the University of California, San Diego School of Medicine found that cholesterol-25-hydroxylase (CH25H) removes cholesterol from cell membranes, preventing the coronavirus SARS-CoV-2 from entering host cells.
-
J Infect Dis: Study reveals the causes of inflammatory response in HIV patients
Time of Update: 2020-11-07
current antiretroviral drugs can prevent new infections, but not HIV RNA, and our results see them as a potentially critical factor driving inflammation in people living with HIV.
-
Cell Rep: A single stem cell can produce millions of T-cells
Time of Update: 2020-11-07
Crooks team showed that a single blood stem cell was enough to produce a large number of T-cells in mice with different subsypes and functions.
-
Science: Gut bacteria protect against the negative effects of harmful radiation
Time of Update: 2020-11-07
the radiation absorbed in clinical settings or during accidental exposure can damage tissue, and in this study, the researchers found that specific bacteria can reduce the damage caused by radiation exposure, enhance the recovery of blood cell production, and repair the gastrointestinal tract.
-
Front Immunol: Link between glare, immune system and Tenascin-C
Time of Update: 2020-11-07
November 1, 2020 /--- -- Researchers at Bochum Ruhr University (RUB) have studied the role of immune responses in glare development in mice.
(Photo: www.pixabay.com) Tenascin-C's inflammatory immune response researchers studied mice lacking Tenascin-C and compared them to animals with the protein.
